Maresin-like 1 Reduces Alzheimer’s Disease Symptoms in Mice
Author Information
Author(s): Shrivastava Pallavi, Lu Yan, Su Shanchun, Kobayashi Yuichi, Zhao Yuhai, Lien Nathan, Masoud Abdul-Razak, Lukiw Walter J., Su Hua, Zhou Li-Ping
Primary Institution: Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans
Hypothesis
Long-term administration of Maresin-like 1 (MarL1) could mitigate Alzheimer’s disease-related brain neuropathogenesis by curbing neuroinflammation and neurodegeneration.
Conclusion
Long-term administration of MarL1 mitigates Alzheimer’s disease-related neuropathogenesis in brains by reducing neuroinflammation and neurodegeneration.
Supporting Evidence
- MarL1 treatment reduced Aβ overload in the brains of 5xFAD mice.
- MarL1 treatment curbed the loss of cholinergic neurons associated with apoptotic degeneration.
- MarL1 treatment decreased microgliosis and promoted anti-inflammatory microglial phenotypes.
- MarL1 treatment improved blood-brain barrier integrity by increasing claudin-5 levels.
Takeaway
Researchers found that a treatment called MarL1 can help protect the brains of mice with Alzheimer's disease by reducing harmful inflammation and helping brain cells survive.
Methodology
The study involved long-term treatment of 5xFAD transgenic mice with MarL1, followed by histological analysis of brain tissues to assess neuroinflammation and neuronal loss.
Limitations
The study was conducted on a specific mouse model, and results may not directly translate to humans; further research is needed to confirm findings.
Participant Demographics
Transgenic 5xFAD mice, aged 1.5 to 12.5 months.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website